These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 32589135)
1. Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: A systematic review of case reports, case series, and observational studies . Hansrivijit P; Puthenpura MM; Ghahramani N Clin Nephrol; 2020 Sep; 94(3):117-126. PubMed ID: 32589135 [TBL] [Abstract][Full Text] [Related]
2. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Garin EH; Reiser J; Cara-Fuentes G; Wei C; Matar D; Wang H; Alachkar N; Johnson RJ Pediatr Nephrol; 2015 Mar; 30(3):469-77. PubMed ID: 25239302 [TBL] [Abstract][Full Text] [Related]
3. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis. Hansrivijit P; Cheungpasitporn W; Thongprayoon C; Ghahramani N BMC Nephrol; 2020 Apr; 21(1):134. PubMed ID: 32293308 [TBL] [Abstract][Full Text] [Related]
4. Abatacept efficacy in steroid-resistant minimal-change disease revealed by the speed of proteinuria reduction after the start of abatacept . Dado D; Parikh S; Ayoub I; Rovin B; Nadasdy T; Hebert L Clin Nephrol; 2018 May; 89(5):376-380. PubMed ID: 29249233 [TBL] [Abstract][Full Text] [Related]
5. Benefit of B7-1 staining and abatacept for treatment-resistant post-transplant focal segmental glomerulosclerosis in a predominantly pediatric cohort: time for a reappraisal. Burke GW; Chandar J; Sageshima J; Ortigosa-Goggins M; Amarapurkar P; Mitrofanova A; Defreitas MJ; Katsoufis CP; Seeherunvong W; Centeno A; Pagan J; Mendez-Castaner LA; Mattiazzi AD; Kupin WL; Guerra G; Chen LJ; Morsi M; Figueiro JMG; Vianna R; Abitbol CL; Roth D; Fornoni A; Ruiz P; Ciancio G; Garin EH Pediatr Nephrol; 2023 Jan; 38(1):145-159. PubMed ID: 35507150 [TBL] [Abstract][Full Text] [Related]
6. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS? Novelli R; Gagliardini E; Ruggiero B; Benigni A; Remuzzi G Am J Physiol Renal Physiol; 2016 Mar; 310(5):F335-41. PubMed ID: 26697986 [TBL] [Abstract][Full Text] [Related]
7. Urinary CD80 as a Replacement for Renal Biopsy for Diagnosis of Pediatric Minimal Change Disease. Ahmed HM; Ezzat DA; Doudar NA; Adel M Iran J Kidney Dis; 2018 Mar; 12(2):107-111. PubMed ID: 29507273 [TBL] [Abstract][Full Text] [Related]
8. CD80 expression and infiltrating regulatory T cells in idiopathic nephrotic syndrome of childhood. Eroglu FK; Orhan D; İnözü M; Duzova A; Gulhan B; Ozaltin F; Topaloglu R Pediatr Int; 2019 Dec; 61(12):1250-1256. PubMed ID: 31513327 [TBL] [Abstract][Full Text] [Related]
9. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Garin EH; Mu W; Arthur JM; Rivard CJ; Araya CE; Shimada M; Johnson RJ Kidney Int; 2010 Aug; 78(3):296-302. PubMed ID: 20485332 [TBL] [Abstract][Full Text] [Related]
10. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Stokes MB; Markowitz GS; Lin J; Valeri AM; D'Agati VD Kidney Int; 2004 May; 65(5):1690-702. PubMed ID: 15086908 [TBL] [Abstract][Full Text] [Related]
11. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance. Cara-Fuentes G; Wei C; Segarra A; Ishimoto T; Rivard C; Johnson RJ; Reiser J; Garin EH Pediatr Nephrol; 2014 Aug; 29(8):1363-71. PubMed ID: 24263531 [TBL] [Abstract][Full Text] [Related]
17. Patients with primary focal segmental glomerulosclerosis with detectable urinary CD80 are more similar to patients with minimal change disease in clinicopathological features. Gong X; Huang J; Zhang Y; Wang F; Wang X; Meng L; Cheng X; Liu G; Cui Z; Zhao M Ren Fail; 2023; 45(2):2279642. PubMed ID: 37942512 [TBL] [Abstract][Full Text] [Related]
18. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Société de Néphrologie. Meyrier A; Noël LH; Auriche P; Callard P Kidney Int; 1994 May; 45(5):1446-56. PubMed ID: 8072258 [TBL] [Abstract][Full Text] [Related]
19. B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS. Delville M; Baye E; Durrbach A; Audard V; Kofman T; Braun L; Olagne J; Nguyen C; Deschênes G; Moulin B; Delahousse M; Kesler-Roussey G; Beaudreuil S; Martinez F; Rabant M; Grimbert P; Gallazzini M; Terzi F; Legendre C; Canaud G J Am Soc Nephrol; 2016 Aug; 27(8):2520-7. PubMed ID: 26701979 [TBL] [Abstract][Full Text] [Related]
20. Urinary CD80 excretion is a predictor of good outcome in children with primary nephrotic syndrome. Ling C; Liu X; Shen Y; Chen Z; Fan J; Jiang Y; Meng Q Pediatr Nephrol; 2018 Jul; 33(7):1183-1187. PubMed ID: 29569191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]